161/1507US=23-E / Câncer
Lin LL, Grigsby PW. Cervical cancer: positron emission tomography and positron emission tomography/computed tomography. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 275-84. ISBN 978-90-481-2917-1.

CANCER CERVICAL; TOMOGRAFIA POR EMISSAO DE POSITRONS; TOMOGRAFIA POR EMISSAO DE POSITRONS/TOMOGRAFIA COMPUTADORIZADA


162/1507US=23-E / Câncer
Ino K, Yamatomoto E, Shibata K, Kajiyama H, Nawa A, Kikkawa F. Cervical cancer: positron emission tomography and positron emission tomography/computed tomography. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 275-84. ISBN 978-90-481-2917-1.

CANCER CERVICAL; TOMOGRAFIA POR EMISSAO DE POSITRONS; TOMOGRAFIA POR EMISSAO DE POSITRONS/TOMOGRAFIA COMPUTADORIZADA


163/1507US=23-E / Câncer
Ino K, Yamatomoto E, Shibata K, Kajiyama H, Nawa A, Kikkawa F. Endometrial cancer: indoleamine 2,3-dioxygenase as a prognostic indicator. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 285-95. ISBN 978-90-481-2917-1.

CANCER DE ENDOMETRIO; 2,3-DIOXIGENASE INDOLEAMINA; INDICADOR DE PROGNOSTICO


164/1507US=23-E / Câncer
Rübben A. Neurofibromatosis type 1-associated malignant melanoma: molecular evidence of inactivation of the NF1 gene. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 301-9. ISBN 978-90-481-2917-1.

NEUROFIBROMATOSE TIPO 1; MELANOMA MALIGNO; EVIDENCIA MOLECULAR DE INATIVACAO DO GENE NF1


165/1507US=23-E / Câncer
Gheysens O, Mottaghy FM. Malignant melanoma: localisation and characterization using fluorodeoxyglucose-positron emission tomography/computed tomography. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 311-22. ISBN 978-90-481-2917-1.

MELANOMA MALIGNO; FLUORODESOXIGLICOSE POR EMISSAO DE POSITRONS; TOMOGRAFIA COMPUTADORIZADA


166/1507US=23-E / Câncer
Roesch A, Landthaler M, Vogt T. Malignant melanoma versus deep penetrating nevus:diagnostic and prognostic immunohistochemistry of dipeptidy1 peptidase IV (methodology). In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 323-31. ISBN 978-90-481-2917-1.

MELANOMA MALIGNO; IMUNO-HISTOQUIMICA; DIPEPTIDE; PEPTIDASE IV; DIPEPTIDIL PEPTIDASE-4; DPP4


167/1507US=23-E / Câncer
Hafner C. Nonmelanoma skin cancer use of Epha1 receptor as a prognostic marker. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 333-40. ISBN 978-90-481-2917-1.

CANCER DE PELE; EPHA1 RECEPTOR


168/1507US=23-E / Câncer
Fiegl M, Mayer J. Pretreated chronic lymphocytic leukemia: use of alemtuzumab. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 343-58. ISBN 978-90-481-2917-1.

LEUCEMIA CRONICA. TRATAMENTO; LINFOCITICA; TRATAMENTO COM USO DE ALEMTUZUMAB


169/1507US=23-E / Câncer
Chatterjee M, Manivannan R, Pande A, Chakraborty T. Immunotherapeutic strategies, radiotherapy, and targeted radionuclide therapy approaches for the treatment of multiple myeloma. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 361-82. ISBN 978-90-481-2917-1.

ESTRATEGIAS DE IMUNOTERAPIA; RADIOTERAPIA; TERAPIA; RADIONUCLIDEOS PARA O TRATAMENTO DO MIELOMA MULTIPLO


170/1507US=23-E / Câncer
Matsuyama A, Hisaoka M, Hashimoto H. Low grade fibromyxoid sarcoma: diagnosis by detecting FUS-CREB3L2 fusion gene using reverse transcription-polymerase chain reaction. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 387-92. ISBN 978-90-481-2917-1.

SARCOMA DE BAIXO GRAU FIBROMIXOIDE; FUS-CREB3L2; GENE DE FUSAO. REACAO EM CADEIA DE POLIMERASE


171/1507US=23-E / Câncer
Terry J, Nielsen TO. Synovial sarcoma: role of TLE1 as a diagnostic immunohistochemical marker. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 393-403. ISBN 978-90-481-2917-1.

SARCOMA SINOVIAL; TLE1 COMO MARCADOR; IMUNO-HISTOQUIMICA. DIAGNOSTICO


172/1507US=23-E / Câncer
Pantanowitz L, Caponetti G, Dezube BJ. The immunohistochemistry of Kaposi's sarcoma. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 405-31. ISBN 978-90-481-2917-1.

IMUNO-HISTOQUIMICA DE SARCOMA DE KAPOSI; SARCOMA DE KAPOSI


173/1507US=23-E / Câncer
Horvai AE. Synovial sarcoma: role of immunohistochemistry and molecular of immunohistochemistry and molecular genetics in diagnosis and prognosis. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 433-47. ISBN 978-90-481-2917-1.

SARCOMA SINOVIAL. DIAGNOSTICO; SARCOMA SINOVIAL. PROGNOSTICO


174/1507US=23-E / Câncer
Fayette J, Cassier P, Brousseau L, Dufresne A, Coquard IR, Alberti L, Méeus P, Decouvelaere AV, Sunyach MP, Ranchère D, Bla JY. Sarcoma: treatment with ecteinascidin-743. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 451-60. ISBN 978-90-481-2917-1.

SARCOMA; TRATAMENTO COM ECTEINASCIDIN-743


175/1507US=26-A / Radioterapia
Hall EJ, Cox JD. Physical and biologic basis of radiation therapy. In: Cox JD, Ang KK. Radiation oncology: rationale, technique, results. 9ª ed. Philadelphia: Elsevier Mosby, 2010. p. 3-49. ISBN 978-0-323-04971-9.

RADIOTERAPIA. BASES FISICAS; RADIOTERAPIA. BASES BIOLOGICAS; BIOLOGIA DO CANCER


176/1507US=26-A / Radioterapia
Zagars GK. Principles of combining radiation therapy and surgery. In: Cox JD, Ang KK. Radiation oncology: rationale, technique, results. 9ª ed. Philadelphia: Elsevier Mosby, 2010. p. 92-101. ISBN 978-0-323-04971-9.

RADIOTERAPIA; CIRURGIA; CONTROLE TUMORAL LOCORREGIONAL; RADIOTERAPIA PRE-OPERATORIA; RADIOTERAPIA POS-OPERATORIA


177/1507US=26-A / Radioterapia
Milas L, Cox JD. Principles of combining radiation therapy and chemotherapy. In: Cox JD, Ang KK. Radiation oncology: rationale, technique, results. 9ª ed. Philadelphia: Elsevier Mosby, 2010. p. 102-17. ISBN 978-0-323-04971-9.

RADIOTERAPIA; QUIMIOTERAPIA; AGENTES QUIMIOTERAPICOS; RADIACAO; DROGAS RADIOATIVAS


178/1507US=26-A / Radioterapia
Ang KK, O'Reilly MS, Meyn RE Jr, Milas L. Principles of combining radiation therapy and molecular therapeutics. In: Cox JD, Ang KK. Radiation oncology: rationale, technique, results. 9ª ed. Philadelphia: Elsevier Mosby, 2010. p. 118-37. ISBN 978-0-323-04971-9.

RADIOTERAPIA; TRATAMENTO DO CANCER; TERAPIA MOLECULAR; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; ANGIOGENESE; AGENTES ANTIANGIOGENICOS; CICLOOXIGENASE; VIA DE SINALIZACAO RAS; TERAPIA GENICA; IMUNOTERAPIA


179/1507US=23-F / Câncer
Albrecht H. Role of antibodies in cancer treatment (an overview). In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods, overviews, head and neck cancer, and thyroid cancer. New York: Springer, 2010. p. 135-52. ISBN 978-90-481-3185-3.

TRATAMENTO DO CANCER; ANTICORPOS NO TRATAMENTO DO CANCER


180/1507US=23-F / Câncer
Lee W, Lockhart AC. Incorporating pharmacogenomics into cancer therapy. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods, overviews, head and neck cancer, and thyroid cancer. New York: Springer, 2010. p. 153-72. ISBN 978-90-481-3185-3.

FARMACOGENOMICA EM TERAPIA DO CANCER


Primeira | Anterior | Próxima | Última